IP21-17: A First in Human Dose Safety and Feasibility Dose Escalation Study of Intraprostatic Drug Eluting Bioabsorbable Implants for Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

IP21-17: A First in Human Dose Safety and Feasibility Dose Escalation Study of Intraprostatic Drug Eluting Bioabsorbable Implants for Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

Friday, May 15, 2026 3:30 PM to 5:30 PM · 1 hr. 59 min. (America/New_York)

146B

Abstract

Speakers

Lodewikus Vermeulen

Lodewikus Vermeulen

UrologistTauranga Urology, New Zealand

Sessions

IP21: Benign Prostatic Hyperplasia: Surgical Therapy & New Technology III

Friday, May 15, 2026 3:30 PM to 5:30 PM

Michael Borofsky · University of Minnesota Medical Center

James Forde · Beaumont Hospital

Nicole Miller · Vanderbilt Univ Med Ctr

Log in

See all the content and easy-to-use features by logging in or registering!